A controversy over the supply of an Indian-made drug to children with Spinal Muscular Atrophy (SMA) has placed the Communist Party of India (Marxist) (CPI-M) on the backfoot in Kerala, with a documentary trail now raising uncomfortable questions about the role of the previous Left Democratic Front (LDF) government in the procurement process. The issue is expected to dominate proceedings when the Kerala Legislative Assembly reconvenes on Monday, 27 October 2026.

The Tactical Move That Misfired

The CPI-M had sought to corner Health Minister K. Muraleedharan by assembling three former women Health Ministers — K.K. Shailaja, P.K. Sreemathy, and Veena George — at a joint press conference to raise concerns about the drug and alleged lapses in its supply to children. What appeared to be a high-profile political offensive, however, has reportedly run into documentary evidence that complicates the party's narrative.

According to reports, a technical committee recommended Natco's medicine on 8 May, and a subsequent communication from the State Mission Director to the Additional Chief Secretary was signed by U.R. Rahul, the State Nodal Officer appointed during the previous LDF government's tenure. This reported paper trail has prompted questions about the CPI-M's attempt to place responsibility entirely on the current United Democratic Front (UDF) government led by Chief Minister V.D. Satheesan.

What the Former Ministers Alleged

Former Health Minister Veena George alleged in a Facebook post that medicine intended for clinical trials had been administered to children through a government medical college. She raised specific concerns about the drug's manufacturing date, shelf life, quality certification, and regulatory approvals. Shailaja and Sreemathy had also flagged concerns over the alleged use of trial medicines and the circumstances surrounding their supply.

The controversy originally surfaced after parents raised alarm over drug packaging reportedly carrying the words 'Doctors' Sample', and complained that adequate information about the medicine had not been provided to them. The precise nature of the labelling, the regulatory status of the drug, and the applicable procurement norms still remain to be fully clarified, according to reports.

Doctors Backing the Government Adds to CPI-M's Woes

What has particularly complicated matters for the Left is that prominent doctors known to be sympathetic to Left politics have reportedly backed the manner in which the V.D. Satheesan government handled the SMA drug issue. This unexpected endorsement from within its own support base has blunted the CPI-M's attack and handed Health Minister Muraleedharan an opportunity to go on the offensive rather than remaining on the defensive.

What to Watch in the Assembly Session

With the Kerala Assembly set to reconvene, the SMA drug controversy is shaping up as a politically charged test of how the CPI-M manages a situation where its own procurement-era decisions are under scrutiny. Notably, this is not the first time that an Opposition campaign in Kerala has been complicated by documentation from the previous government's own tenure. The Health Minister is now widely expected to use the Assembly floor to present the documentary trail, potentially reversing the burden of accountability. All sides have yet to provide a full, definitive account of the procurement timeline and regulatory approvals involved.